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DOI 10.1016/j.ccr.2011.12.027SUMMARYTumor-initiating cells have been suggested to be rare in many cancers. We tested this in mouse malignant
peripheral nerve sheath tumors (MPNSTs) and found that 18% of primary and 49% of passaged MPNST
cells from Nf1+/; Ink4a/Arf/ mice formed tumors upon transplantation, whereas only 1.8% to 2.6% of
MPNST cells from Nf1+/; p53+/ mice did. MPNST cells of both genotypes require laminin binding to b1-
integrin for clonogenic growth. Most MPNST cells from Nf1+/; Ink4a/Arf/ mice expressed laminin,
whereas most MPNST cells from Nf1+/; p53+/ mice did not. Exogenous laminin increased the percentage
of MPNST cells from Nf1+/; p53+/ but not Nf1+/; Ink4a/Arf/ mice that formed tumorigenic colonies.
Tumor-forming potential is common among MPNST cells, but the assay conditions required to detect it
vary with tumor genotype.INTRODUCTION
The question of which cells contribute to cancer growth and
progression has fundamental implications for therapy. If tumor
growth and metastasis are driven primarily by rare, or at least
infrequent, cancer stem cells then cancer might be more effec-
tively treated by specifically targeting the cancer stem cells
(Reya et al., 2001; Pardal et al., 2003; Dick, 2008). On the other
hand, if many cancer cells are capable of driving tumor growth
and metastasis it will be necessary to eliminate most or all
cancer cells.
Evidence suggests that small populations of cancer stem
cells drive the growth and progression of a number of cancers,
including some germ lineage cancers (Kleinsmith and Pierce,
1964; Illmensee and Mintz, 1976), myeloid leukemias (Lapidot
et al., 1994; Bonnet and Dick, 1997; Yilmaz et al., 2006;
Oravecz-Wilson et al., 2009), breast cancers (Al-Hajj et al.,
2003), gliomas (Singh et al., 2004), and colon cancers (DalerbaSignificance
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that could be detected in some assays. Although laminin bind
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phenotype, can therefore require different assay conditions to
240 Cancer Cell 21, 240–252, February 14, 2012 ª2012 Elsevier Inc.et al., 2007; O’Brien et al., 2007; Ricci-Vitiani et al., 2007;
Merlos-Sua´rez et al., 2011). In each case, transplantation of
cancer cells into highly immunocompromised mice revealed
a small, phenotypically distinct subpopulation of cells that
was uniquely capable of transferring disease and forming
phenotypically diverse nontumorigenic progeny. This suggests
that some cancers are hierarchically organized, with small
numbers of cancer stem cells that sustain tumor growth
by forming large numbers of cancer cells with limited prolif-
erative potential (Reya et al., 2001; Pardal et al., 2003; Dick,
2008).
In contrast to this model, human melanomas (Quintana et al.,
2008, 2010), mouse melanomas (Held et al., 2010), and some
mouse leukemias (Kelly et al., 2007; Williams et al., 2007) have
many cells with tumorigenic potential. For example, 30% of
single cells obtained directly from melanomas in patients and
over 50% of cells obtained from primary mouse melanomas
can form tumors in highly immunocompromised mice (Quintanauencies of tumorigenic cells, which were similar upon trans-
ce. However, tumor genotype influenced the laminin expres-
n exogenous laminin and the frequency of tumorigenic cells
ing to b1-integrin was important for clonogenic growth, the
mors of different genotypes, even with the same malignant
detect the full range of cells with tumorigenic potential.
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raise three critical questions.
(1) Is melanoma unique among solid cancers in having
common tumorigenic cells?
(2) Can high frequencies of tumorigenic cells be detected in
immunocompetent recipients for some cancers or does
the immune system play such a central role in the control
of tumor-initiating cells that common tumorigenic cells
can only be detected in immunocompromised recipients?
To address this question it is necessary to examine
mouse models of cancer, which can be transplanted
into syngeneic recipients without a confounding xenoge-
neic immune barrier that rejects human cells by mecha-
nisms that are very different from the autologous immune
responses that can occur within patients.
(3) Finally, what other factors influence the frequency of
cancer cells that can form tumors?
Malignant peripheral nerve sheath tumors (MPNSTs) are
aggressive soft tissue sarcomas that arise within peripheral
nerves. Most MPNSTs arise in the context of Neurofibromatosis
type 1, a hereditary tumor syndrome caused bymutations inNF1
that encodes Neurofibromin, a GTPase-activating protein that
negatively regulates Ras signaling (Rubin and Gutmann, 2005).
About 30% of NF1 patients develop benign plexiform neurofi-
bromas, which can transform into MPNSTs. Plexiform neurofi-
bromas and MPNSTs arise from Schwann cells in peripheral
nerves (Zhu et al., 2002; Joseph et al., 2008; Zheng et al.,
2008). Beyond the loss of NF1 function, CDKN2A (p16Ink4a),
CDKN2D (p14Arf; the human ortholog of mouse p19Arf), and
TP53 are often inactivated in MPNSTs by deletion or promoter
hypermethylation (Menon et al., 1990; Perrone et al., 2003; Age-
sen et al., 2005). Mutations of these genes in mice also lead to
the development of MPNSTs. Thus, mice that are heterozygous
for a deletion of both Nf1 and p53 (Nf1+/; p53+/; Cichowski
et al., 1999; Vogel et al., 1999) and mice heterozygous for Nf1
and deficient for Ink4a/Arf (Nf1+/; Ink4a/Arf/; Joseph et al.,
2008) develop MPNSTs.
We developed in vitro and in vivo assays to determine the
frequency of MPNST cells with tumorigenic potential in these
mouse models of MPNST.RESULTS
More Tumorigenic Cells Were Detected among Primary
MPNST Cells from Nf1+/–; Ink4a/Arf–/– Mice
Nf1+/; Ink4a/Arf/ and Nf1+/; p53+/ mice were backcrossed
onto a C57BL/Ka background (at least six generations) and then
aged to monitor the development of MPNSTs. Approximately
25% to 50% of Nf1+/; Ink4a/Arf/ mice and Nf1+/;
p53+/ mice developed MPNSTs on the legs and abdomens,
typically between 4 and 7 months of age, as previously reported
(Cichowski et al., 1999; Joseph et al., 2008). Tumors of both
genotypes grew rapidly and at comparable rates (data not
shown). Three of four primary and four of four secondary
MPNSTs from Nf1+/; p53+/ mice exhibited p16Ink4a and
p19Arf expression, whereas p16Ink4a and p19Arf were not de-
tected in MPNSTs from Nf1+/; Ink4a/Arf/ mice, as expectedC(Figure S1 available online). p53 was not detected in most
MPNSTs from Nf1+/; p53+/ mice, as expected (Vogel et al.,
1999), but was detected in most MPNSTs from Nf1+/; Ink4a/
Arf/ mice (data not shown).
We sacrificed Nf1+/; Ink4a/Arf/ and Nf1+/; p53+/ mice at
6.1 ± 0.9 or 5.3 ± 1.4 (mean ± SD)months of age, respectively, for
analysis. Tumors of both genotypes contained tightly packed
spindle cells with tapered nuclei arranged in a fascicular pattern
(Figures 1A–1F). Of 25 tumors analyzed, 24 were focally positive
for the Schwann cell marker S100b (Figures 1A and 1D). In
tumors of both genotypes, we observed frequent mitotic figures
(an average of 1.1 ± 0.7 in Nf1+/; Ink4a/Arf/ MPNSTs and
1.6 ± 0.6 in Nf1+/; p53+/ MPNSTs per high power field, objec-
tive x ocular magnification = 4003) and a high frequency of Ki-67
positive cells (39 ± 16% for Nf1+/; Ink4a/Arf/ and 52 ± 9% for
Nf1+/; p53+/ MPNSTs; Figures 1C, 1F, and 1G).
We also administered bromo-deoxyuridine (BrdU) to tumor-
bearing mice. After 6 hr of administration, 10% and 14% of cells
were BrdU+ in primary MPNSTs from Nf1+/; Ink4a/Arf/ and
Nf1+/; p53+/ mice, respectively. Similar results were obtained
when secondary MPNSTs were analyzed: 9% and 10 ± 6%
of cells from MPNSTs obtained from Nf1+/; Ink4a/Arf/ and
Nf1+/; p53+/ mice incorporated BrdU, respectively. After 5 or
10 days of administration, over 80% of cells were BrdU+ in
MPNSTs of both genotypes (Figure 1H). MPNSTs from both
Nf1+/; Ink4a/Arf/ andNf1+/; p53+/mice therefore contained
similarly high frequencies of rapidly dividing cells.
To obtain MPNST cells for experiments, primary tumors of
comparable size from mice of both genotypes were enzymati-
cally dissociated and stained with antibodies. Only tumors that
were confirmed to be MPNSTs by histopathology were included
in our analysis. The cells were sorted by flow cytometry to
exclude debris (based on light scatter), dead cells (40,6-diami-
dino-2-phenylindole+ (DAPI+)), hematopoietic cells (Ter119+ or
CD45+), and endothelial cells (CD31+; Figure 1I). Viable cells
that were negative for hematopoietic/endothelial markers were
used in all experiments. These cells comprised an average of
48 ± 17% and 44 ± 14% (mean ± SD) of nucleated cells in
MPNSTs from Nf1+/; Ink4a/Arf/ and Nf1+/; p53+/ mice,
respectively.
We injected MPNST cells subcutaneously, into sciatic nerves,
or under the kidney capsules of wild-type C57BL/Ka mice. The
kidney capsule is a common site for heterologous cell grafting,
where many cell types are able to efficiently engraft. We rarely
observed the formation of tumors after subcutaneous injection,
even when we injected large numbers of cells, but transplanted
cells readily formed tumors in sciatic nerve and under the kidney
capsule at higher cell doses (Table S1). At lower cell doses the
cells engrafted more efficiently under the kidney capsule, where
the cells were retained after injection (Table S1). Injection of cells
into the endoneurial space increased pressure within nerves and
led to the ejection of the injected material through the needle
track, rendering the assay nonquantitative in peripheral nerve.
For this reason, subsequent experiments to quantify the
frequency of cells with tumorigenic potential were conducted
by transplanting cells under the kidney capsule.
We transplanted aliquots of 100 cells, ten cells, or single cells
from ten primary MPNSTs obtained from Nf1+/; Ink4a/Arf/
mice and eight primary MPNSTs from Nf1+/; p53+/mice underancer Cell 21, 240–252, February 14, 2012 ª2012 Elsevier Inc. 241
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Figure 1. Nf1+/–; Ink4a/Arf–/– and Nf1+/–;
p53+/– Mice Develop MPNSTs that Contain
a High Frequency of Proliferating Cells
(A–F) Paraffin sections of Nf1+/; Ink4a/Arf/ and
Nf1+/; p53+/ MPNSTs were stained with anti-
bodies against S100b (A and D), hematoxylin and
eosin (B and E), and antibodies against Ki-67 (C
and F). Sections were counterstained with hema-
toxylin (blue) in (A), (D), (C), and (F). Each panel
reflects a different section.
(G) The percentage of MPNST cells that were Ki-
67-positive was determined for four tumors of
each genotype on at least 20 high-power fields
(4003 magnification, ocular x objective) for each
tumor.
(H) The percentage of MPNST cells (that stained
negatively for blood or endothelial markers) inmice
bearing primary (p) or secondary (transplanted into
wild-type mice; s) MPNSTs treated with BrdU
for either 6 hr or 5 or 10 days that were BrdU-
positive. The data reflect one primary and eight
secondary tumors from Nf1+/; Ink4a/Arf/ mice
and three primary and nine secondary tumors
from Nf1+/; p53+/ mice. All statistics represent
mean ± SD.
(I) Isolation of MPNST cells from primary tumors
using flow cytometry.
See also Figure S1 and Tables S1 and S2.
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Tumor-Initiating Cells Are Common in MPNSTsthe kidney capsule of C57BL/Ka mice. We monitored the mice
for at least 15 weeks after transplantation. When tumors became
evident by palpation or at the end of the experiment, the mice
were sacrificed for gross and histological examination. Sorted
events from the debris fraction (Figure 1I) did not form tumors
upon transplantation and cells from the fractions that stained
positively for hematopoietic or endothelial markers rarely formed
tumors (Table S2). When viable MPNST cells from the nonhema-
topoietic/nonendothelial fraction of Nf1+/; Ink4a/Arf/ mice
were injected, 28 of 29 mice (97%) injected with 100 cells, 28
of 39 mice (72%) injected with 10 cells, and 16 of 76 mice
(21%) injected with single cells formed MPNSTs (Table 1).
Almost all of these tumors were observed within ten weeks after
transplantation and appeared histologically similar to the primary
tumors from which they derived (Figure S2A). Limit dilution anal-
ysis indicated that 18 ± 14% (mean ± SD; range = 6% to 53%) of
cells from primary MPNST formed tumors after transplantation.
Tumorigenic cells were therefore common within primary
MPNSTs obtained from Nf1+/; Ink4a/Arf/ mice.
When nonhematopoietic/nonendothelial cells from primary
tumors obtained from 8 Nf1+/; p53+/ mice were injected, 24
of 37 mice (65%) injected with 100 cells, 6 of 43 mice (14%) in-
jected with 10 cells, and 2 of 38 mice (5%) injected with single
cells formed MPNSTs (Table 1). All of these tumors were
observed within ten weeks after transplantation and appeared242 Cancer Cell 21, 240–252, February 14, 2012 ª2012 Elsevier Inc.histologically similar to the primary
tumors from which they derived (Fig-
ure S2B). Limit dilution analysis indicated
that an average of 1.8 ± 1.6% (mean ±SD;
range = 0.6% to 5.0%) of cells from
these MPNSTs formed tumors aftertransplantation. The frequency of tumorigenic cells in MPNSTs
from Nf1+/; p53+/ mice was therefore significantly lower
(10-fold, p = 0.008) in this assay than in MPNSTs from Nf1+/;
Ink4a/Arf/mice. This demonstrates that MPNST genetic back-
ground can affect tumorigenic cell frequency.
MPNSTs from Nf1+/–; Ink4a/Arf–/– Mice Retain Higher
Frequencies of Tumorigenic Cells upon Secondary
Transplantation
We wondered whether the reduced frequency of tumorigenic
cells within primary MPNSTs from Nf1+/; p53+/ mice reflected
increased infiltration of normal cells into these tumors as
compared to MPNSTs from Nf1+/; Ink4a/Arf/ mice. To test
this, we performed secondary transplants of dissociated cells
from tumors that arose under the kidney capsule of primary
recipient mice. Transplanted MPNST cells form focal masses
that are distinct from normal kidney tissue. We reasoned that
only cancer cells would proliferate extensively in primary recip-
ient mice, reducing or eliminating normal cells from the
passaged tumors. Therefore, if normal cells within primary
MPNSTs from Nf1+/; p53+/ mice diluted the cancer cells,
then secondary transplantation of these MPNSTs should elimi-
nate the difference in tumorigenic cell frequency among
MPNSTs of different genotypes. When MPNST cells from eleven
first-generation grafts from five different primary MPNSTs from
Table 1. Tumor Formation by Primary MPNST Cells
Tumor
Injected Cell Dose
(No. of Tumors/
No. of Injections)
Cells that
Formed
Tumors (%)
95%
CI (%)100 Cells 10 Cells 1 Cell
Nf1+/; Ink4a/Arf/ mice
10 3/3 nd 1/8 13 1.9–95
11 1/2 1/2 2/6 16 4.3–61
12 5/5 4/6 6/8 27 11–65
14 3/3 4/4 0/8 18 6.6–48
15 3/3 3/6 0/7 6.0 2.1–18
16 4/4 6/6 4/10 53 22–100
17 4/4 4/5 1/9 15 5.9–37
23 nd nd 1/10 10 nd
29 nd 2/5 1/10 6.2 1.9-20
35 5/5 4/5 nd 16 5.4–48
Total 28/29
(97%)
28/39
(72%)
16/76
(21%)
18 6.8–55
Nf1+/; p53+/ mice
1 1/3 0/4 1/10 0.7 0.1–3.0
3 4/5 0/5 nd 1.3 0.5–3.6
4 4/5 2/5 1/10 2.6 1.0–6.8
5 4/5 1/5 0/10 1.7 0.6–4.3
6 2/4 0/5 0/8 0.6 0.1–2.2
7 5/5 3/8 nd 5.0 1.8–13
8 4/6 0/5 nd 1.0 0.3–2.6
9 0/4 0/6 nd nd nd
Total 24/37
(65%)
6/43
(14%)
2/38
(5%)
1.8** 0.5–4.0
Tumorigenic cell frequency significantly differed in this assay between
MPNSTs from Nf1+/; Ink4a/Arf/ and Nf1+/; p53+/mice (**p = 0.008).
nd, not determined; CI, confidence interval.
For tumor histology, see Figure S2.
Table 2. Tumor Formation after Secondary Transplantation of
MPNST Cells
Tumor
Injected Cell Dose Cells that
Formed
Tumors (%)
95%
CI (%)100 Cells 10 Cells 1 Cell
Nf1+/; Ink4a/Arf/ mice
9 (N = 1) nd nd 4/8 50 nd
10 (N = 1) nd nd 5/9 56 nd
11 (N = 3) nd 3/3 8/25 40 21–76
12 (N = 4) nd 11/12 15/38 40 24–65
17 (N = 2) nd nd 12/19 58 nd
Total nd 14/15
(93%)
44/99
(44%)
49 22–71
Nf1+/; p53+/ mice
3 (N = 2) 7/9 2/11 1/10 1.8 0.9–3.6
4 (N = 2) 3/10 0/10 0/10 0.3 0.1–1.0
5 (N = 1) 4/4 1/5 2/10 5.7 1.9–17
8 (N = 1) 3/4 3/6 nd 2.5 0.9–7.1
Total 17/27
(63%)
6/32
(19%)
3/30
(10%)
2.6** 0.9–7.3
Tumorigenic cell frequency significantly differed in this assay between
MPNSTs from Nf1+/; Ink4a/Arf/ and Nf1+/; p53+/ mice (**, p =
2 3 105).
nd, not determined; CI, confidence interval.
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Tumor-Initiating Cells Are Common in MPNSTsNf1+/; Ink4a/Arf/ mice were injected into secondary recipi-
ents, 14 of 15 (93%) ten-cell injections and 44 of 99 (44%)
single-cell injections gave rise to tumors (Table 2). Virtually all
tumors became palpable within ten weeks of transplantation.
Limit dilution analysis indicated that 49 ± 8.6% (mean ± SD;
range = 40% to 58%) of cells from each of these serially trans-
planted MPNST formed tumors after transplantation. Thus,
approximately half of the cells within MPNSTs are capable of
forming tumors by the time the MPNSTs have been passaged
once.
When MPNST cells from six first-generation grafts from four
primary MPNSTs from Nf1+/; p53+/ mice were injected into
secondary recipients, 6 of 32 (19%) injections of 10 cells and 3
of 30 (10%) injections of single cells gave rise to tumors (Table
2). All tumors became palpable within ten weeks of transplanta-
tion. Limit dilution analysis indicated that an average of 2.6 ±
2.3% (mean ± SD; range = 0.3% to 5.7%) of cells from each of
these serially transplanted MPNSTs formed tumors after trans-
plantation. Thus, MPNSTs from Nf1+/; Ink4a/Arf/ mice re-
tained a significantly (19-fold; p = 2 3 105) higher frequency
of tumorigenic cells than MPNSTs from Nf1+/; p53+/ mice,Ceven upon secondary transplantation. This suggests that the
reduced frequency of tumorigenic cells within primary MPNSTs
from Nf1+/; p53+/ mice did not reflect the presence of normal
cells in these tumors.
MPNSTs from Nf1+/–; Ink4a/Arf–/– Mice Retain Higher
Frequencies of Tumorigenic Cells upon Transplantation
into NOD/SCID ILR2gnull Mice
To test whether MPNST cells from Nf1+/; p53+/ mice were
more immunogenic than MPNST cells from Nf1+/; Ink4a/Arf/
mice we transplanted dissociated cells from primary MPNSTs
into immunocompetent C57BL/Ka recipients or into highly
immunocompromised NOD/SCID ILR2gnull mice, which lack B,
T, and natural killer cells (Shultz et al., 2005). We found that
16%–20% of cells from two primary MPNSTs from Nf1+/;
Ink4a/Arf/ mice formed tumors irrespective of whether they
were transplanted into C57BL/Ka or NOD/SCID ILR2gnull mice.
Similarly, 1%–5% of MPNST cells from Nf1+/; p53+/ mice
formed tumors in C57BL/Ka recipients and 0.6%–2.5% formed
tumors in NOD/SCID ILR2gnull recipients (Table 3). These results
indicate that the recipient immune system has little effect on the
frequency of MPNST cells that form tumors after transplantation,
irrespective of genotype, and the reduced frequency of tumori-
genic MPNST cells from Nf1+/; p53+/ mice cannot be ex-
plained by increased immunogenicity.
Higher Percentage of MPNST Cells from Nf1+/–; Ink4a/
Arf–/– Mice Formed Colonies in Nonadherent Culture as
Compared to Nf1+/–; p53+/– Mice
We cultured primary mouse MPNST cells, 1 cell/well in 96 well
plates for 10–14 days in nonadherent conditions (Molofsky
et al., 2003). We found that 35 ± 20% (mean ± SD) of MPNSTancer Cell 21, 240–252, February 14, 2012 ª2012 Elsevier Inc. 243
Table 3. Tumor Formation by Primary MPNST Cells in Immunocompetent C57BL/Ka Mice and Immunocompromised NOD/SCID
ILR2gnull Mice
Tumor Recipient Mice
Injected Cell Dose
Tumorigenic Cells (%) 95% CI100 Cells 10 Cells 5 Cells
Nf1+/; Ink4a/Arf/ (35) C57BL/Ka 5/5 4/5 16 5.4–48
Nf1+/; Ink4a/Arf/ (35) NOD/SCID IL2Rgnull 5/5 4/5 16 5.4–48
Nf1+/; Ink4a/Arf/ (40) C57BL/Ka 4/7 17 6.2–46
Nf1+/; Ink4a/Arf/ (40) NOD/SCID IL2Rgnull 5/8 20 7.9–49
Nf1+/; p53+/ (7) C57BL/Ka 5/5 3/8 5.0 1.8–13
Nf1+/; p53+/ (7) NOD/SCID IL2Rgnull 4/5 3/7 2.5 1.0–6.5
Nf1+/; p53+/ (28) C57BL/Ka 3/5 1/8 1.0 0.4–2.8
Nf1+/; p53+/ (28) NOD/SCID IL2Rgnull 2/5 1/8 0.6 0.2–2.1
The frequency of tumorigenic cells and the 95% confidence interval (CI) around this frequency were determined by extreme limiting dilution (ELDA)
software (see Experimental Procedures for software URL).
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Tumor-Initiating Cells Are Common in MPNSTscells from 12 differentNf1+/; Ink4a/Arf/mice formed colonies,
and 62% of these colonies (62 of 100) formed tumors after trans-
plantation under the kidney capsule of C57BL/Ka mice. In
contrast, only 4.1 ± 3.4% of MPNST cells from 12 Nf1+/;
p53+/ mice formed colonies, and 32% of these colonies (13 of
40) formed tumors after transplantation into C57BL/Ka mice
(Table 4). Averaging across tumors, 23 ± 21% of single MPNST
cells from Nf1+/; Ink4a/Arf/ mice and 2.0 ± 2.9% of MPNST
cells from Nf1+/; p53+/ mice formed tumorigenic colonies.
This indicates that tumorigenic cells were also significantly less
common (11-fold, p = 0.02) in MPNSTs from Nf1+/; p53+/
mice as compared toNf1+/; Ink4a/Arf/mice, evenwhen these
cells were initially propagated in culture instead of transplanting
uncultured cells directly in vivo (as in Tables 1, 2, 3).
The reduced colony formation by MPNST cells from Nf1+/;
p53+/ mice was largely attributable to increased cell death as
compared to MPNST cells from Nf1+/; Ink4a/Arf/ mice. Ten
to 14 days after adding MPNST cells to culture, we carefully
examined the wells. We found that 43 ± 2.4% of wells in which
we had plated single MPNST cells from Nf1+/; Ink4a/Arf/
mice did not contain any cells, indicating that these cells must
have undergone cell death. In contrast, 69 ± 13% of wells in
which we had plated single MPNST cells from Nf1+/; p53+/
mice did not contain any cells. This suggests that a significantly
(p = 0.02) higher percentage of single MPNST cells from Nf1+/;
p53+/ mice underwent cell death after being added to culture.
The remaining wells that did not contain colonies but were not
empty contained small numbers of cells (<10), indicating that
these cells underwent a limited number of divisions.
We examined the number of apoptotic cells in MPNSTs in vivo
and in MPNST cells cultured under nonadherent conditions
(Figure S3). MPNST tumors in Nf1+/; Ink4a/Arf/ and Nf1+/;
p53+/mice in vivo contained similar frequencies of cleaved cas-
pase-3 positive cells. In culture, we found that a significantly
higher percentage of cells from Nf1+/; p53+/ mice compared
to Nf1+/; Ink4a/Arf/ mice expressed cleaved caspase-3 after
12 days of culture (5.8 ± 3.4% versus 2.2 ± 2.4; mean ± SD; p =
0.03). MPNST cells from Nf1+/; Ink4a/Arf/ mice are therefore
more likely to survive nonadherent culture than MPNST cells
from Nf1+/; p53+/ mice, even though no difference in the
frequency of apoptotic cells was observed in tumors in vivo.
This suggests that differences in the rate of cell death between244 Cancer Cell 21, 240–252, February 14, 2012 ª2012 Elsevier Inc.MPNSTs from different genetic backgrounds are context-
dependent. We therefore decided to explore whether changes
in assay conditions could increase the frequency of clonogenic
MPNST cells.
Laminin Is Expressed by More MPNST Cells in Nf1+/–;
Ink4a/Arf–/– Mice than in Nf1+/–; p53+/– Mice
One commonway of improving the growth and survival of cells in
culture is by growing cells adherently on extracellular matrix,
rather than nonadherently, as described above. Adherent culture
on laminin, in particular, enhances the growth and survival of
neural stem/progenitor cells and glioma cells (Sun et al., 2008;
Pollard et al., 2009; Lathia et al., 2010). Because MPNST cells
from Nf1+/; p53+/ mice did not exhibit increased cell death
in vivo, in contrast to what was observed in culture, wewondered
whether MPNST cells were exposed to laminin in the tumor envi-
ronment in vivo. We examined the expression of laminin-111/-
211 (laminin a1/b1/g1 and a2/b1/g1) on sections through
MPNSTs from Nf1+/; Ink4a/Arf/ and Nf1+/; p53+/ mice
(Figures 2A–2D). In MPNSTs fromNf1+/; Ink4a/Arf/mice lam-
inin-111/-211 was widely expressed by most tumor cells,
including cancer cells and vascular/perivascular stromal cells
(Figures 2B and 2D). In contrast, in MPNSTs from Nf1+/;
p53+/ mice laminin appeared to be expressed by many fewer
cells and to be mainly vascular/perivascular (Figures 2A and 2C).
We found that dissociated MPNST cells from Nf1+/; Ink4a/
Arf/ mice exhibited much stronger laminin-111/211 staining
than MPNST cells from Nf1+/; p53+/ mice (Figure 2E). Indeed,
70 ± 11% of MPNST cells from Nf1+/; Ink4a/Arf/ mice and
28 ± 22% of MPNST cells from Nf1+/; p53+/ mice stained
with laminin by flow cytometry. This demonstrates that most
MPNST cells from Nf1+/; Ink4a/Arf/ mice carry laminin with
them after dissociation, whereas only a minority of MPNST cells
from Nf1+/; p53+/ mice do so. If laminin promotes the survival
or proliferation of MPNST cells, then MPNST cells from Nf1+/;
p53+/ mice would be expected to depend more upon exoge-
nous laminin, as compared to MPNST cells from Nf1+/; Ink4a/
Arf/ mice.
We administered a 6 hr pulse of BrdU to mice and then stained
sections through their MPNSTs with antibodies against BrdU
and laminin-111/211 to assess the localization of dividing cells
relative to laminin-expressing cells. BrdU+ cells tended to
Table 4. Colony Formation by Single Primary MPNST Cells
Cultured under Nonadherent Conditions and Tumor Formation by
These Colonies after Transplantation In Vivo
Tumor
Single Cells
that Formed
Colonies (%)
Tumors/
Colonies
Injected (%)
Single Cells that
Formed Tumorigenic
Colonies (%)
Nf1+/; Ink4a/Arf/ mice
6 26 2/9 (22) 5.8
7 47 4/5 (80) 38
8 39 2/7 (29) 11
9 14 5/11 (45) 6.2
10 22 5/10 (50) 11
11 34 8/13 (62) 21
12 66 12/13 (92) 60
14 11 4/5 (80) 8.7
15 7.6 2/7 (29) 2.2
16 38 9/11 (82) 31
17 66 9/10 (90) 59
23 55 nd nd
Mean ± SD 35 ± 20 62/100 (62) 23 ± 21
Nf1+/; p53+/ mice
1 10 nd nd
2 3.1 nd nd
3 6.1 0/10 (0) 0.0
4 2.4 1/5 (20) 0.5
5 0.5 nd nd
6 8.3 4/4 (100) 8.3
7 0.5 nd nd
8 5.6 4/10 (40) 2.2
9 1.6 nd nd
12 0.5 1/1 (100) 0.5
13 8.1 1/6 (17) 1.4
14 2.9 2/4 (50) 1.5
Mean ± SD 4.1 ± 3.4** 13/40 (32) 2.0 ± 2.9*
For each tumor, we determined the percentage of cells that formed colo-
nies in culture and the percentage of these colonies that formed tumors
upon transplantation into C57BL/Ka mice. The last column represents
the product of these statistics, that is, the percentage of MPNST cells
that formed tumorigenic colonies.
**p = 3 3 105; *p = 0.02. All statistics represent mean ± SD.
nd, not determined.
For data on cell death in culture, see Figure S3.
Cancer Cell
Tumor-Initiating Cells Are Common in MPNSTslocalize adjacent to laminin-expressing cells and regions of the
tumor that lacked laminin staining also had fewer dividing cells.
MPNSTs from Nf1+/; Ink4a/Arf/ and Nf1+/; p53+/ mice
included 9 ± 5 and 8 ± 2% (mean ± SD) BrdU+ cells, respectively
(Figures 2F–2H). InMPNSTs fromNf1+/; Ink4a/Arf/mice, lam-
inin was widely expressed such that almost all cells (88 ± 18%),
including nearly all BrdU+ cells (97 ± 1%), were adjacent to lam-
inin-stained cells (Figures 2F and 2H). However, in MPNSTs from
Nf1+/; p53+/ mice, laminin was more restricted in its expres-
sion such that only 39 ± 6% of MPNST cells were adjacent to
laminin-stained cells. Yet, most BrdU+ cells (83 ± 7%) remained
adjacent to laminin-stained cells in these tumors (Figures 2G andC2H). Therefore, BrdU+ cells were more than twice as likely as all
MPNST cells to localize adjacent to laminin-expressing cells in
MPNSTs from Nf1+/; p53+/ mice. This is consistent with the
possibility that laminin may promote the proliferation of MPNST
cells, though laminin staining may also be associated with
vasculature that promotes proliferation through other
mechanisms.
MPNSTs from Nf1+/–; p53+/– but Not Nf1+/–; Ink4a/Arf–/–
Mice Form More Colonies on Laminin
If laminin promotes clonogenic growth by MPNST cells and
MPNST cells from Nf1+/; p53+/ mice are less likely to carry
laminin after dissociation (Figure 2E), then exogenous laminin
might stimulate clonogenic growth by MPNST cells from
Nf1+/; p53+/ mice to a greater extent than MPNST cells from
Nf1+/; Ink4a/Arf/ mice. To test this, we compared colony
formation by singleMPNST cells from both genetic backgrounds
in nonadherent cultures and in adherent cultures on laminin-111
(Figure 3A). Adherent culture on laminin did not affect the
percentage of MPNST cells from Nf1+/; Ink4a/Arf/ mice that
formed colonies compared to nonadherent cultures (Figure 3A);
however, it significantly increased the percentage of MPNST
cells from Nf1+/; p53+/ mice that formed colonies from 6.7 ±
9.8% to 25 ± 18% (p = 0.003; Figure 3A). Although the
percentage of cells that formed colonies varied between tumors,
the rate of colony formation on laminin was always at least as
high as in nonadherent cultures, and the effect was statistically
significant in a paired t test (p = 0.003). Adherent culture on fibro-
nectin or collagen may have enhanced the rate of tumor forma-
tion to some extent, but the effects were variable among tumors
and not statistically significant (Table S3). Exposure to laminin
thus increased colony-formation by MPNST cells from Nf1+/;
p53+/ mice but not Nf1+/; Ink4a/Arf/ mice, consistent with
the difference in endogenous laminin expression between these
genetic backgrounds.
Adherent colonies grown on laminin by MPNST cells from
Nf1+/; p53+/ mice, but not Nf1+/; Ink4a/Arf/ mice, also
tended to be larger than those that grew in nonadherent cultures
(data not shown). Consistent with this, a significantly higher
frequency of cells within colonies fromNf1+/; p53+/mice incor-
porated a pulse of BrdUwhen cultured on laminin-111 compared
to nonadherent culture conditions, whereas adherent culture on
laminin did not significantly affect the rate of BrdU incorporation
into colonies cultured fromNf1+/; Ink4a/Arf/mice (Figure 3B).
To assess the proliferative potential of MPNST cells that
formed colonies on laminin, we dissociated the colonies that
arose from single cells and replated them into secondary
cultures. Twenty-three of 24 (96%) colonies from three primary
MPNSTs obtained from Nf1+/; p53+/ mice gave rise to
secondary colonies, yielding an average of 2573 ± 626
secondary colonies per primary colony. An average of 30 ±
10% of cells within the primary colonies formed secondary colo-
nies upon replating. These results suggest that many MPNST
cells from Nf1+/; p53+/ mice have the potential to proliferate
extensively if assayed under permissive conditions.
To assess whether colony-forming MPNST cells from Nf1+/;
p53+/ mice had the potential to form tumors in vivo, we disso-
ciated individual colonies and injected the cells under the
kidney capsule of C57BL/Ka mice. In these experiments,ancer Cell 21, 240–252, February 14, 2012 ª2012 Elsevier Inc. 245
CD31
laminin
laminin
CD31/laminin
CD31/laminin
DAPI
A
laminin DAPIMECA-32
2
n
d
a
r
y
 
a
n
t
i-
b
o
d
y
 
c
o
n
t
r
o
l
MECA-32
/laminin
MECA-32 laminin
MECA-32
/laminin DAPI la
m
in
in
-1
11
/2
11
la
m
in
in
-1
11
/2
11
70 ± 11%
28 ± 22%
BrdU/laminin-111/211 DAPI/laminin-111/211
B
CD31 DAPI
DAPI
C
D
F BrdU/laminin-111/211 DAPI/laminin-111/211G
H
E
goat anti-rabbitgoat anti-rat
100µm100µm
100µm
100µm
100µm
100µm
100µm
N
f
1
+
/
-
;
I
n
k
4
a
A
r
f
 
-
/
-
N
f
1
+
/
-
;
 
p
5
3
+
/
-
N
f
1
+
/
-
;
I
n
k
4
a
A
r
f
 
-
/
-
N
f
1
+
/
-
;
 
p
5
3
+
/
-
N
f
1
+
/
-
;
I
n
k
4
a
A
r
f
 
-
/
-
N
f
1
+
/
-
;
 
p
5
3
+
/
-
Nf1
+/-
; Ink4aArf 
-/-
Nf1
+/-
; p53
+/-
Figure 2. Laminin Is Expressed by Most
MPNST Cells from Nf1+/–; Ink4a/Arf–/– Mice
but Only by a Subset of MPNST Cells from
Nf1+/–; p53+/– Mice
(A–D) MPNSTs from Nf1+/; p53+/ (A and C) and
Nf1+/; Ink4a/Arf/ (B and D) mice were stained
with antibodies against laminin-111/211, CD31,
andMECA-32 (to label endothelial cells), as well as
DAPI to identify nuclei.
(E) Dissociated MPNST cells, after exclusion of
blood and endothelial cells, were stained with
antibodies against laminin-111/211 and analyzed
by flow cytometry. Numbers reflect the
percentage of cells that stainedmore strongly than
isotype control (3-5 MPNSTs/genotype, p = 0.02
between the two genotypes).
(F–H) Mice bearing MPNSTs were treated with
BrdU for 6 hr and cryosections were stained with
DAPI, as well as antibodies against laminin-111/
211 and BrdU. In MPNSTs from Nf1+/; p53+/
mice, BrdU+ cells were 2.1-fold more likely (p =
0.04) than the average MPNST cell to localize
adjacent to laminin (the data reflect three tumors/
genotype and 2,200–3,200 cells/tumor). All
statistics are mean ± SD.
Cancer Cell
Tumor-Initiating Cells Are Common in MPNSTs25 ± 18% of the MPNST cells formed adherent colonies on
laminin-111 and 36 of 54 colonies formed tumors in vivo (Fig-
ure 3C). Thus, 19 ± 13% of single MPNST cells from Nf1+/;
p53+/ mice formed tumorigenic colonies in the presence of
laminin-111. The histological appearance of the tumors that
arose from transplanted colonies was similar to primary
MPNSTs (Figure S4).
Given the increased colony formation by MPNST cells on lam-
inin, we tested whether the tumorigenicity of uncultured primary
MPNST cells in vivo was increased by mixing the cells with Ma-
trigel (of which laminin is the main component; Kleinman and
Martin, 2005). Suspension of primary MPNST cells in Matrigel
prior to injection approximately doubled the frequency MPNST
cells from both genetic backgrounds that formed tumors
(Figures 3D and 3E). Limit dilution analysis indicated that 4.7%
of primary MPNST cells from Nf1+/; p53+/ mice and 30% of
primary MPNST cells from Nf1+/; Ink4a/Arf/ mice formed
tumors when injected under the kidney capsule with Matrigel.
These results further emphasize that the frequency of tumorigenic246 Cancer Cell 21, 240–252, February 14, 2012 ª2012 Elsevier Inc.MPNST cells varies with tumor genotype
and assay conditions and that many
primary MPNST cells are capable of
forming tumors in immunocompetent
mice.
To test whether endogenous laminin
expression distinguishes intrinsically
tumorigenic from intrinsically nontumori-
genic subpopulations of MPNST cells,
we sorted laminin-positive and laminin-
negative MPNST cells from both genetic
backgrounds and transplanted them
under the kidney capsule of C57BL/Ka
mice. Both laminin-positive and laminin-negative MPNST cells formed tumors, though the rate of tumor
formation by the laminin-positive cells was significantly higher
in both genetic backgrounds (2.2-fold difference, p = 0.02 for
cells from Nf1+/; Ink4a/Arf/ mice; 2.5-fold difference, p =
0.049 for Nf1+/; p53+/ mice; Figures 3F and 3G). Because
6.6% and 1.3% of laminin negative MPNST cells from Nf1+/;
Ink4a/Arf/ mice and Nf1+/; p53+/ mice, respectively, formed
tumors in vivo, our data do not support the idea that laminin nega-
tive cells intrinsically lack tumor-forming capacity. Rather, the
data suggest that laminin increases the clonogenic potential of
MPNST cells but that it does not matter whether the laminin is
intrinsic or extrinsic to the cells. It remains possible there is a hier-
archy of tumorigenic and nontumorigenic MPNST cells that can
be identified with other markers. Thus, our data demonstrate
thatmanyMPNSTcells arecapableof forming tumors, depending
on assay conditions and genetic background, but the formal
question of whether MPNSTs exhibit a hierarchical organization
consistent with the cancer stem cell model is not addressed by
our study.
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Figure 3. MPNST Cells from Nf1+/–; p53+/– Mice Formed More Colonies When Plated Adherently on Laminin
(A) Single MPNST cells from Nf1+/; Ink4a/Arf/ (N = 6) and Nf1+/; p53+/ mice (N = 7) were sorted into individual wells of 96-well plates and cultured either
nonadherently or adherently on laminin-111. **, p = 0.003 by paired t test between adherent and nonadherent cultures of cells from Nf1+/; p53+/ mice.
(B) 10,000 MPNST cells from Nf1+/; Ink4a/Arf/ or Nf1+/; p53+/ mice (three tumors each) were cultured nonadherently or adherently on laminin-111 for
1–3 days. Then a 3 hr pulse of BrdU was administered (*p < 0.05). Error bars in (A) and (B) represent SD.
(C) Adherent colonies from single MPNST cells fromNf1+/; p53+/mice grown on laminin-111 were trypsinized, injected under the kidney capsules of C57BL/Ka
mice, and then monitored for the ability to form tumors for 15 weeks. The last column represents the percentage of MPNST cells that formed adherent colonies
and that went on to form tumors upon transplantation of the colonies in vivo (the product of columns 1 and 2). nd, not determined.
(D and E) Freshly isolated MPNST cells from Nf1+/; p53+/ (D) or Nf1+/; Ink4a/Arf/ (E) mice were transplanted under the kidney capsule of C57BL/Ka mice,
with or without Matrigel, and then monitored for tumor formation for at least 15 weeks.
(F and G) Freshly dissociated laminin-positive or laminin-negative MPNST cells from Nf1+/; p53+/ (F) or Nf1+/; Ink4a/Arf/ (G) mice were transplanted under
the kidney capsule of C57BL/Ka mice. Cells that stained positively for laminin were more likely to form tumors in both genetic backgrounds (p = 0.02 for Nf1+/;
Ink4a/Arf/ mice and p = 0.049 for Nf1+/; p53+/ mice, paired t test).
See also Table S3 and Figure S4.
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Figure 4. MPNST Cells Expressed Laminin
Receptors and Blocking Antibodies against
b1 Integrin Decreased Colony Formation on
Laminin
(A and B) Expression of indicated integrins by
MPNST cells from Nf1+/; p53+/ (A) and Nf1+/;
Ink4a/Arf/ (B) mice. Numbers reflect the
percentages of cells that stained more strongly
than isotype control.
(C and D) Colony formation by MPNST cells from
Nf1+/; p53+/ mice on the indicated substrate
treated with function-blocking antibodies against
a1 (C) or a6 (D) integrin. (Iso means isotype control
antibody.)
(E) Representative pictures of colonies formed by
MPNST cells from Nf1+/; p53+/ mice in the
presence of function blocking antibodies against
b1 integrin or isotype control.
(F and G) The effect of blocking antibody against
b1 integrin on the percentage of cells that formed
colonies. *, p = 0.02 for Nf1+/; p53+/mice (F) and
p = 0.05 for Nf1+/; Ink4a/Arf/ (G) on laminin. No
significant difference on plastic or collagen.
(H) Western blots of extracts from MPNSTs cells
obtained from Nf1+/; p53+/ mice using anti-
bodies against phospho-ERK1/2. Cells were
cultured for three days under nonadherent condi-
tions (NA), adherently on plastic (AP), or adherently
on laminin-111 (AL). Error bars represent SD.
See also Figure S5.
Cancer Cell
Tumor-Initiating Cells Are Common in MPNSTsLaminin Promotes the Survival and Proliferation of
MPNST Cells via b1 Integrin
a1b1, a2b1, a3b1, a6b1, a7b1, and a6b4 integrins are laminin
receptors (Miner and Yurchenco, 2004). By flow cytometry, we
found that integrins a2, a6, and b1 were widely expressed on
the surface of MPNST cells fromNf1+/; Ink4a/Arf/ andNf1+/;
p53+/mice (Figure 4A). Integrins a1 (Figure 4A) and b4 (data not
shown) were rarely expressed at detectable levels. Thus,
MPNST cells appear to express multiple laminin receptors,
including a2b1 and a6b1. Laminin-111/211 is also strongly ex-
pressed by basement membranes under the kidney capsule
(Figure S5), just as in MPNSTs (Figure 2), potentially explaining
why the kidney capsule creates a permissive environment for
tumor formation by MPNST cells.
We examined whether antibodies that block the binding of
laminin-111 to integrin receptors would impede colony forma-248 Cancer Cell 21, 240–252, February 14, 2012 ª2012 Elsevier Inc.tion. We were unable to find a preserva-
tive-free antibody against a2-integrin
suitable for use in these experiments.
Addition of blocking antibodies against
a1-integrin (Figure 4C) or a6-integrin (Fig-
ure 4D) to culture did not affect the
percentage of MPNST cells from Nf1+/;
p53+/ mice that formed colonies or the
size of colonies. In contrast, addition of
blocking antibodies against b1-integrin
(Milner and Campbell, 2002) but not
isotype control antibody significantly
decreased the percentage of MPNST
cells from Nf1+/; p53+/ mice (Figure 4F)
and Nf1+/; Ink4a/Arf/ mice (Figure 4G) that formed colonies
on laminin-111, as well as the size of these colonies (Figure 4E),
but did not affect the percentage of cells that formed adherent
colonies on uncoated plastic or collagen 1 (Figures 4F and 4G).
These data demonstrate that laminin binding to b1-integrin-
containing receptors increases the clonogenicity of MPNST cells
from both genetic backgrounds.
Laminin promotes the survival of Schwann cells (Yu et al.,
2005), and MPNSTs arise from Schwann cells (Zhu et al., 2002;
Joseph et al., 2008; Zheng et al., 2008). Integrin receptors signal
through the ERK pathway (Guo and Giancotti, 2004), and ERK
provides a survival and proliferation signal to Schwann lineage
cells (Newbern et al., 2011) and MPNST cells (Ambrosini et al.,
2008). We found that adherent culture on laminin-111 increased
the levels of phosphorylated ERK1/2 in MPNST cells from some
Nf1+/; p53+/ mice compared to nonadherent culture or
Cancer Cell
Tumor-Initiating Cells Are Common in MPNSTsadherent culture on plastic (Figure 4H). Laminin binding to b1-
integrin may therefore promote the survival and proliferation of
MPNST cells by increasing ERK signaling.
DISCUSSION
Our data demonstrate that cells with tumorigenic potential are
common in MPNSTs of both genotypes but that tumors with
different genotypes sometimes require different assay condi-
tions to read-out the full spectrum of cells with tumorigenic
potential. If tumor genotype commonly influences the assay
conditions that must be used to detect tumorigenic cells then
assay conditions that detect the full spectrum of tumorigenic
cells in one cancer patient may not detect the full spectrum of
tumorigenic cells in other patients with the same cancer type.
Studies of mouse lung cancers (Curtis et al., 2010), mouse
mammary cancers (Vaillant et al., 2008), and mouse myeloid
leukemias (Somervaille and Cleary, 2006; Kennedy et al., 2007)
have shown that cancers from different genetic backgrounds
have different frequencies of tumorigenic cells, differences in
the extent to which they follow a cancer stem cell model, or
tumorigenic cells that express different markers. Human acute
lymphoblastic leukemia samples that differ with respect to
CDKN2A/B genotype also display differences in leukemogenic
cell frequencies in immunocompromised mice (Notta et al.,
2011). We demonstrate here that tumors of different genotypes
can have similarly high frequencies of cells with tumorigenic
potential but can require different assay conditions to detect
these tumorigenic cells. Furthermore, we show that sarcomas
sometimes contain common tumorigenic cells.
Our data suggest that the binding of laminin to b1-integrin-
containing receptors promotes the survival and proliferation of
MPNST cells. MPNST cells from Nf1+/; p53+/ and Nf1+/;
Ink4a/Arf/ mice depended upon the binding of laminin to b1-
integrin for proliferation and survival (Figure 4), but MPNST cells
from Nf1+/; Ink4a/Arf/ mice did not require the addition of
exogenous laminin to culture (Figures 3A and 3B), presumably
because these cells were much more likely to carry endogenous
laminin as compared to MPNST cells from Nf1+/; p53+/ mice.
Suspension of MPNST cells from either genetic background in
Matrigel doubled the frequency of cells that formed tumors
in vivo (Figures 3D and 3E), and dividing cells in primary MPNSTs
in vivo almost always had contact with laminin-expressing cells
(Figures 2F–2H). Thus, laminin appears to be one important
determinant of clonogenicity in MPNST cells, but it does not
appear to matter whether the laminin is intrinsic or extrinsic to
the MPNST cells.
Our results raise the possibility that the failure to restore critical
extracellular matrix cues after tumor dissociation may lead to
underestimates of the frequency of tumor-initiating cells. The
common use of sphere-formation assays in nonadherent
cultures to identify tumor-initiating cells may exacerbate this
problem by depriving dissociated cancer cells of extracellular
matrix.
Our data demonstrate that melanoma is not unique among
solid tumors in containing common cells with tumorigenic poten-
tial. We have demonstrated that at least 30% of human mela-
noma cells obtained directly from patients have the potential to
form tumors upon transplantation into NOD/SCID ILR2gnullCmice (Quintana et al., 2008, 2010). An even higher percentage
of single cells obtained from primary mouse melanomas can
form tumors upon transplantation (Held et al., 2010). Whereas
some cancers are likely to have only rare cells with the potential
to proliferate extensively, other cancers are likely to contain
common tumorigenic cells, and it remains uncertain what frac-
tion of cancers fall in each category. Some mouse leukemias
contain common leukemogenic cells (Somervaille and Cleary,
2006; Kelly et al., 2007; Williams et al., 2007). However, other
hematopoietic malignancies contain only rare leukemogenic
cells (Lapidot et al., 1994; Kennedy et al., 2007), even when
mouse leukemias are transplanted into histocompatible mice
(Yilmaz et al., 2006; Oravecz-Wilson et al., 2009). A recent study
discovered that human hematopoietic stem cells engraft more
efficiently in female as compared to male mice (Notta et al.,
2010), a variable that has rarely been taken into account in
xenotransplantation experiments. Thus, whereas many solid
cancers have appeared to contain only rare tumorigenic cells
(Ishizawa et al., 2010), an open question concerns the extent
to which existing assays underestimate the frequency of cells
with tumorigenic potential.
Our observation that approximately 20% of MPNST cells from
Nf1+/; p53+/ and Nf1+/; Ink4a/Arf/ mice have the potential
to form tumors is likely an underestimate, because there are
likely to be important features of the tumor environment that
are not adequately modeled in the tumorigenesis assays we
used. For example, it is possible that tumor-associated fibro-
blasts or tumor-infiltrating inflammatory cells promote the
survival or proliferation of MPNST cells (Le et al., 2009; Staser
et al., 2010) in a way that is not initially replicated when we place
small numbers of dissociated MPNST cells in culture or under
the kidney capsule in vivo. More sophisticated models of this
tumor microenvironment could reveal even higher frequencies
of MPNST cells that have the potential to form tumors.
Although we found that cells with tumorigenic potential were
common in mouse MPNSTs, a separate question concerns the
spectrum of cells that are actually fated to contribute to disease
progression in vivo. Our data demonstrating that many cells
divide rapidly within MPNSTs (Figure 1H) suggests that many
cells contribute to tumor growth. However, it is also possible
that many of these cells divide only a limited number of times
and that only a small fraction of the cells with the potential to
proliferate extensively actually does so in vivo. Fate-mapping
studies will be required to assess whether many or few MPNST
cells actually contribute extensively to tumor growth or disease
progression in vivo.
The question of whether MPNSTs follow a cancer stem cell
model, in which cancer cells are hierarchically organized into
intrinsically different subpopulations of tumorigenic and nontu-
morigenic cells, also remains an open question. One possibility
is that MPNSTs contain common tumorigenic cells with no hier-
archical organization. Another possibility is that MPNSTs contain
a shallow hierarchy in which common tumorigenic cells differen-
tiate into nontumorigenic MPNST cells. Even if the latter is the
case, MPNST would be quite different from other cancers sug-
gested to follow the cancer stem cell model.
Our data demonstrate that cells with tumorigenic potential are
common in MPNSTs and that tumors from different genetic
backgrounds can require different assay conditions to read-outancer Cell 21, 240–252, February 14, 2012 ª2012 Elsevier Inc. 249
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Tumor-Initiating Cells Are Common in MPNSTsthe full spectrum of cells with tumorigenic potential. This
suggests that efforts to quantify the frequency of tumorigenic
cells in human cancers may be complicated by confounding
effects of tumor genotype on assay conditions. As assays
improve it is likely that estimates of tumorigenic cell frequencies
will continue to increase in many cancers. It remains to be deter-
mined what fraction of cancers have only rare tumorigenic cells
and what fraction of cancers have common tumorigenic cells.
Determining which cancers fall in each category has funda-
mental implications for therapy as attempts to target small
subpopulations of cancer cells are not likely to improve the
treatment of cancers in which many cells can drive disease
progression.
EXPERIMENTAL PROCEDURES
Mice
Nf1+/ (Jacks et al., 1994)mice were bred with Ink4aArf/mice (Serrano et al.,
1996) to yield compoundmutantNf1+/; Ink4a/Arf/mice (Joseph et al., 2008).
Nf1+/; Ink4a/Arf/mice andNf1+/; p53+/mice (Cichowski et al., 1999) were
backcrossed on aC57BL/Kabackground for at least six generations. Genotyp-
ingwas performed as described by Joseph et al. (2008). All animal experiments
were performed in accordance with protocols approved by the University of
Michigan’s Committee on the Use and Care of Animals.
Dissociation of MPNSTs and Flow Cytometry
Tumors were harvested from mice and minced using a scalpel. Minced tissue
was washed in Ca2+ and Mg2+-free Hank’s buffered salt solution (HBSS; Invi-
trogen, Grand Island, NY, USA), centrifuged, and treated for 20 min at 37C
with a mixture of 25% Ca2+ and Mg2+-free HBSS, 25% Collagenase IV (Wor-
thington [Lakewood, NJ, USA]; resuspended to 2,000 U/ml in HBSS containing
Ca2+ and Mg2+, Invitrogen), and 50% Trypsin-EDTA solution (0.05%, Invitro-
gen) with constant agitation. The reaction was quenched with staining medium
consisting of L15 medium (Invitrogen), 1 mg/ml BSA (Sigma-Aldrich, St. Louis,
MO, USA), 10 mM HEPES (BioWhittaker # 17-738E), 1% penicillin/strepto-
mycin (Invitrogen), supplemented with DNase 1 (100 U/ml; Sigma), and filtered
through 70 mm nylon filter (Fisher Scientific, Ottawa, Ontario). The cells were
centrifuged, resuspended in staining medium, and then counted on a hemocy-
tometer. Cells were stained with antibodies against CD31 (BioLegend, San
Diego, CA, USA), CD45 (eBioscience, San Diego, CA, USA), and Ter119
(BioLegend) in 200 ml of staining medium for 20 min at 4C. The cells were
then washed and resuspended in staining medium supplemented with DAPI
(10 mg/ml; Sigma). To evaluate the expression of laminin receptors, cells
were stained with antibodies against integrin a1 (BD Biosciences, San Diego,
CA, USA), a2 (BD Biosciences), a6 (eBioscience), and integrin b1 (BD Biosci-
ences), as well as appropriate secondary antibodies prior to staining with
blood lineage markers. Flow cytometry was performed with a FACSVantage
SE-dual laser, three-line flow cytometer, or with a FACSAria II (Becton Dickin-
son, Franklin Lakes, NJ, USA).
Cell Culture
Cells were typically cultured in 96-well tissue culture plates (Corning, Lowell,
MA, USA) at a density of 1 cell/well. For nonadherent cultures, ultra-low
binding plates (Corning) were used. For adherent cultures, plates were coated
with fibronectin (Biomedical Technologies, Stoughton, MA, USA), laminin-111
(Invitrogen), or collagen-1 (BD Bioscience), all at 50mg/ml. The culture medium
for both adherent and nonadherent cultures was based on a 5:3mixture of Dul-
becco’s modified eagle medium -low:Neurobasal medium (Invitrogen). The
medium was supplemented with 15% chick embryo extract (prepared as
described; Stemple and Anderson, 1992), 20 ng/ml recombinant human
bFGF (R&D Systems, Minneapolis, MN), 20 ng/ml IGF1 (R&D Systems), 1%
N2 supplement (Invitrogen), 2% B27 supplement (Invitrogen), 50 mM 2-mer-
captoethanol (Acros Organics), 35 ng/ml retinoic acid (Sigma), and 1% peni-
cillin/streptomycin (Invitrogen). In some cases, themediumwas supplemented
with laminin-111 or fibronectin, both at 50 mg/ml. All cultures were maintained
at 37C in 6% CO2/balance air. For experiments using blocking antibodies,250 Cancer Cell 21, 240–252, February 14, 2012 ª2012 Elsevier Inc.cells were cultured at a density of 50–100 cells/well on 24-well plates on plastic
or laminin-111 (50 mg/ml) in the presence or absence of antibodies against
integrin a1 (BD Bioscience), a6 (clone GoH3; R&D Systems), or b1 (BD Biosci-
ence) or corresponding isotype controls (all at 10 mg/ml). Colony formationwas
assessed after 5–8 days.
Kidney Capsule Injections
MPNST cells were resuspended in 30 ml of sterile staining medium. Mice were
anesthetized by intraperitoneal injection of ketamine/xylazine. After shaving
the skin and prepping with betadine (Fisher Scientific), a 1 cm longitudinal
incision was made in the skin of the abdomen and in the body wall above
the kidney. Cell suspensions were injected under the capsule of the exposed
kidney using an insulin syringe with a 31G needle (BD Bioscience). In some
cases, 50% Matrigel (BD Bioscience) was added to the cell suspension. The
incisions were closed using absorbable suture (Tevdek, Genzyme Surgical
#7-734). Animals were given antibiotic water (1.1 g/l neomycin sulfate and
106 U/l polymixin B sulfate) and monitored closely. Tumor formation was
assessed by weekly palpation of the abdomen or by magnetic resonance
imaging for at least 15 weeks. The frequency of tumorigenic cells and the
95% confidence interval were calculated using extreme limiting dilution soft-
ware (http://bioinf.wehi.edu.au/software/elda/index.html).
SUPPLEMENTAL INFORMATION
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